BRME1
Break repair meiotic recombinase recruitment factor 1
Also known as: BRME1_HUMAN, C19orf57, MEIOK21, MGC11271
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q0VDD7
- Gene
- BRME1
- Ensembl
- ENSG00000132016
- Chromosome
- 19
- Canonical length
- 668 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to enable damaged DNA binding activity. Predicted to be involved in meiosis I; protein localization to site of double-strand break; and spermatogenesis. Predicted to be located in chromosome. Predicted to be active in site of double-strand break. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
668 residues, UniProt reviewed canonical sequence.
>Q0VDD7|BRME1
1 MTKRKKLRTS GEGLCPPKPL KNPRLGDFYG DPQSSMLGCL HHPEEPEGKL GPVPSTQQHG
61 EEPGKAVSSS PDEETGSPCR LLRQPEKEPA PLPPSQNSFG RFVPQFAKSR KTVTRKEEMK
121 DEDRGSGAFS LETIAESSAQ SPGCQLLVET LGVPLQEATE LGDPTQADSA RPEQSSQSPV
181 QAVPGSGDSQ PDDPPDRGTG LSASQRASQD HLSEQGADDS KPETDRVPGD GGQKEHLPSI
241 DSEGEKPDRG APQEGGAQRT AGAGLPGGPQ EEGDGVPCTP ASAPTSGPAP GLGPASWCLE
301 PGSVAQGSPD PQQTPSRMGR EGEGTHSSLG CSSLGMVVIA DLSTDPTELE ERALEVAGPD
361 GQASAISPAS PRRKAADGGH RRALPGCTSL TGETTGESGE AGQDGKPPGD VLVGPTASLA
421 LAPGSGESMM GAGDSGHASP DTGPCVNQKQ EPGPAQEEAE LGGQNLERDL EGFRVSPQAS
481 VVLEHREIAD DPLQEPGAQQ GIPDTTSELA GQRDHLPHSA DQGTWADSLA VELDFLLDSQ
541 IQDALDASDF EAPPEQLFPS GNKPGPCWPG PSSHANGDPV AVAKAQPRTF VGIQASEASR
601 MEDATNVVRG LIVELSNLNR LIMGTHRDLE AFKRLNYRKT KLGGKAPLPY PSKGPGNIPR
661 GDPPWRELLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BRME1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.72
- Highest tissue expression
- 14 nTPM
Expression across tissuesHPA
Tissue
- testis: 14 nTPM
- esophagus: 5.2 nTPM
- skin: 4.9 nTPM
- pancreas: 4.8 nTPM
- cerebellum: 4.5 nTPM
- small intestine: 3.8 nTPM
Single-cell type
- early primary spermatocytes: 17 nCPM
- tuft cells: 12 nCPM
- bergmann glia: 3.9 nCPM
- differentiating spermatogonia: 3.3 nCPM
- astrocytes: 3 nCPM
- brain excitatory neurons: 3 nCPM
Immune cell
- gdT-cell: 0.8 nTPM
- plasmacytoid DC: 0.5 nTPM
- naive CD8 T-cell: 0.4 nTPM
- memory CD8 T-cell: 0.2 nTPM
- total PBMC: 0.2 nTPM
- MAIT T-cell: 0.1 nTPM
Brain region
- cerebellum: 4.4 nTPM
- white matter: 3.3 nTPM
- cerebral cortex: 3 nTPM
- hippocampal formation: 2.9 nTPM
- medulla oblongata: 2.9 nTPM
- pons: 2.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.78
- gnomAD pLI
- 0
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Break repair meiotic recombinase recruitment factor 1
- Break repair meiotic recombinase recruitment factor 1
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of BRME1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BRME1 as an antibody target. Whether an autoantibody or antibody against BRME1 could matter depends on whether native BRME1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BRME1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label BRME1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...